Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

315.45 +6.97 (+2.26%)
Streaming Delayed Price Updated: 12:54 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk ↗
Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility. 
Via Benzinga
Topics World Trade
News headline image
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount ↗
Via The Motley Fool
News headline image
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations ↗
The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market. 
Via Investor's Business Daily
News headline image
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
How Do Investors Really Feel About Alnylam Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
News headline image
Is Alnylam Pharmaceuticals Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
FDA Approves Sanofi's Hemophilia Drug ↗
FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year. 
Via Benzinga
News headline image
Competitive Analysis In The ATTR-CM Field ↗
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
News headline image
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock ↗
Alnylam's Amvuttra wins FDA approval for ATTR-CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity. 
Via Benzinga
News headline image
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? ↗
Best performing large-cap stocks last week: Alnylam Pharma up 16%, Roku up 14%, Elbit Systems up 13%, Venture Global up 12%, Boeing up 11%. Are they in your portfolio? 
Via Benzinga
News headline image
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio ↗
Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio. 
Via Investor's Business Daily
News headline image
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps ↗
Alnylam's Amvuttra receives FDA approval for ATTR-CM, expanding its use and securing broad insurance coverage as global regulatory reviews continue. 
Via Benzinga
News headline image
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
How Do Investors Really Feel About Alnylam Pharmaceuticals? ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.